QIAGEN OmicSoft and Biomedical Knowledge Base

Checkpoint inhibitor and immuno-oncology investigation leveraging curated high-quality public ‘omics data

15 views
June 11, 2025

While there is great interest in the scientific community to investigate drug targets and biomarkers from public immune-oncology data, such investigation is hindered by the difficulty in finding and combining related datasets to perform large-scale meta-analyses. This webinar will focus on how high-quality curated genomic repositories such as QIAGEN OmicSoft Lands immediately allows in-depth investigations across diverse data sources (GEO, CPTAC, TCGA, GTEx and more) to discover and validate candidate checkpoint inhibitor drug targets and biomarkers.

You will learn how to do the following in the graphical user interface and through APIs:

- Easily identify relevant samples using extensive manually curated clinical metadata

- Visualize and identify checkpoint inhibition biology related drug target and biomarkers expression patterns using expression data (RNA-seq, scRNA-seq, proteomics etc.)

- Reveal how the expression of a group of biomarkers (or genes/proteins of interest) correlates in normal and disease tissue

Related videos

QIAGEN OmicSoft and Biomedical Knowledge Base

Knowledge graphs and more: Analytics-driven drug discovery using advanced biomedical...

1,981 views July 19, 2022

High-quality biomedical relationships knowledge is the cornerstone of modern...

QIAGEN OmicSoft and Biomedical Knowledge Base

Identify mutation hotspots in a gene of interest

728 views May 08, 2019

In several cancers, IDH1 is frequently mutated at arginine 132, which alters...

QIAGEN OmicSoft and Biomedical Knowledge Base

Transcriptomics, Proteomics and Metabolic Changes in Post-Natal Mouse Heart analyzed with...

653 views November 07, 2019

In the full talk, Jean-Noël Billaud, Ph.D. Senior Principal Scientist,...

QIAGEN OmicSoft and Biomedical Knowledge Base

Supercharge your AI in drug discovery with high-quality biomedical data

637 views October 11, 2023

If you’re working in pharma or biotech, you likely rely on artificial...